Abstract
Objective: We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy.
Case Summary: A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of renal failure, abnormal urinalysis, and renal biopsy with inflammatory infiltrate in the interstitium confirmed a diagnosis of AIN. The patient subsequently developed IHA, which was confirmed by peripheral blood smear results and positive Coombs’ test. The patient recovered after dialysis therapy and 2 days of intravenous methylprednisolone (500mg/day) followed by oral prednisolone (60 mg/day), which was rapidly tapered and stopped within 3 weeks.
Conclusions: To our knowledge, cefpodoxime-induced AIN and IHA are unprecedented. Physicians should be aware that drug-induced AIN and hemolysis can be associated with cefpodoxime proxetil.
Keywords: Acute interstitial nephritis, acute kidney injury, adverse reaction, cefpodoxime proxetil, immune hemolytic anemia, early treatment.
Current Drug Safety
Title:Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis
Volume: 8 Issue: 2
Author(s): Hakki Yilmaz, Mukadder Ayse Bilgic, Nuket Bavbek and Ali Akcay
Affiliation:
Keywords: Acute interstitial nephritis, acute kidney injury, adverse reaction, cefpodoxime proxetil, immune hemolytic anemia, early treatment.
Abstract: Objective: We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy.
Case Summary: A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of renal failure, abnormal urinalysis, and renal biopsy with inflammatory infiltrate in the interstitium confirmed a diagnosis of AIN. The patient subsequently developed IHA, which was confirmed by peripheral blood smear results and positive Coombs’ test. The patient recovered after dialysis therapy and 2 days of intravenous methylprednisolone (500mg/day) followed by oral prednisolone (60 mg/day), which was rapidly tapered and stopped within 3 weeks.
Conclusions: To our knowledge, cefpodoxime-induced AIN and IHA are unprecedented. Physicians should be aware that drug-induced AIN and hemolysis can be associated with cefpodoxime proxetil.
Export Options
About this article
Cite this article as:
Yilmaz Hakki, Bilgic Ayse Mukadder, Bavbek Nuket and Akcay Ali, Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis, Current Drug Safety 2013; 8 (2) . https://dx.doi.org/10.2174/15748863113089990028
DOI https://dx.doi.org/10.2174/15748863113089990028 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Dimethyloxallyl Glycine-Incorporated Borosilicate Bioactive Glass Scaffolds for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects
Current Drug Delivery Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy